The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

Robert F. Kennedy Jr. petitioned the FDA to revoke authorization of the shots when they were in high demand and thousands of ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.